DelveInsight’s “Actinic Keratosis Market Insights, Epidemiology, and Market Forecast- 2036′′ report offers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Actinic Keratosis Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/actinic-keratosis-market

Key Takeaways from the Actinic Keratosis Market Report

• On May 22, 2026- Biofrontera Inc. initiated a phase III study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment for actinic keratosis (AK) on the extremities and neck/trunk.
• On April 22, 2026- Sun Pharmaceutical Industries Inc. conducted a study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the upper extremities.
• Actinic keratosis is more prevalent in men and older populations.
• The United States represented the largest patient pool among the 7MM, accounting for the majority of diagnosed cases.
• Actinic keratosis has a higher prevalence in fair-skinned individuals.
• Among EU4 and the UK, Germany had the highest number of prevalent cases of actinic keratosis in 2025.
• The leading Actinic Keratosis Companies such as Athenex, Almirall, Vidac Pharma, Promius Pharma and others.
• Promising Actinic Keratosis Therapies such as AVX001, VDA-1102, Fluorouracil, Imiquimod 3.75% Cream, Tirbanibulin 2.5 mg ointment, KX01 ointment 1%, Tretinoin 0,05% cream, Bimiralisib, Solcera, LAS41005, LAS106521 and others.

Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Actinic Keratosis Market Forecast @ Actinic Keratosis Treatment Market

Actinic Keratosis Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Actinic Keratosis
• Total Diagnosed Prevalent Cases of Actinic Keratosis
• Age-specific Cases of Actinic Keratosis
• Gender-specific Cases of Actinic Keratosis
• Total Treated Cases of Actinic Keratosis

Download the Report to understand which factors are driving Actinic Keratosis epidemiology trends @ Actinic Keratosis Prevalence

Approved Therapies for Actinic Keratosis

• Tirbanibulin (KLISYRI): Almirall

Tirbanibulin (KLISYRI), ointment 1%, is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis of the face or scalp. It has demonstrated efficacy and safety, with a convenient 5-day application regimen, representing the shortest treatment duration among available topical therapies for actinic keratosis. In December 2020, Almirall announced that the US FDA had approved tirbanibulin for the topical treatment of actinic keratosis of the face or scalp. According to the company’s 2025 annual presentation, the net sales of tirbanibulin were approximately USD 38 million for 2025.

• Aminolevulinic acid hydrochloride (AMELUZ): Biofrontera Pharma GmbH

Aminolevulinic acid hydrochloride topical gel, 10% is a photosensitizing agent indicated for the treatment of actinic keratosis of the face and scalp when used in combination with photodynamic therapy (PDT), enabling selective destruction of atypical keratinocytes after light activation. Aminolevulinic acid hydrochloride was initially approved by the US FDA in May 2016 for the treatment of actinic keratosis of the face and scalp in combination with photodynamic therapy. In February 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission approved an extension of the marketing authorization for aminolevulinic acid hydrochloride, allowing its use with artificial daylight photodynamic therapy for the treatment of actinic keratosis. According to the company’s FY 2025 results presentation, AMELUZ recorded more than 25% growth in the German market and achieved a market share of approximately 73%.

Actinic Keratosis Pipeline Analysis

• Tuvatexib (VDA-1102): Vidac Pharma

Tuvatexib (VDA-1102) is an investigational topical therapy being developed for the treatment of actinic keratosis. The drug is designed to selectively target abnormal keratinocytes in sun-damaged skin while minimizing effects on surrounding healthy tissue. VDA-1102 works through a novel mechanism of action that dissociates the abnormally overexpressed Hexokinase-2 (HK2) enzyme from the mitochondrial pore, aiming to restore normal cellular metabolism and selectively induce programmed cell death in pathological tissue while sparing healthy cells. The therapy is currently in late-stage of clinical trial (phase II/III).

• RLS-1496: Rubedo Life Sciences

RLS-1496, the lead candidate of Rubedo Life Sciences, is in early clinical trial stage, being developed for topical and oral administration as a potential first-in-class selective GPX4 modulator targeting pathological senescent (“aged”) cells involved in chronic degenerative and aging-related conditions, including dermatologic disorders such as actinic keratosis, as well as immunology and inflammation, metabolic diseases, sarcopenia, and neurodegenerative disorders.

Get In-Depth Knowledge on Actinic Keratosis Market Trends and Forecasts with DelveInsight @ Actinic Keratosis Treatment Market

Actinic Keratosis Market Outlook

The treatment landscape for actinic keratosis has historically relied on lesion-directed and field-directed therapies aimed at removing visible lesions and treating surrounding sun-damaged skin. Common approaches include cryotherapy, topical agents such as 5-fluorouracil and imiquimod, and photodynamic therapy (PDT). The approved therapy tirbanibulin is a microtubule inhibitor that disrupts cell proliferation and induces apoptosis. Its short 5-day topical regimen represents a meaningful advancement in convenience and adherence compared to older treatments.

Actinic Keratosis Therapies and Companies

• Almirall S.A.: Tirbanibulin 2.5 mg ointment
• PharmaEssentia: KX01 ointment 1%
• Vidac Pharma: 10% VDA-1102
• TORQUR: Bimiralisib
• Infectopharm Arzneimittel GmbH: Solcera

Actinic Keratosis Drugs Landscape

The pipeline for actinic keratosis is evolving with several investigational therapies focusing on improved efficacy, tolerability, and field cancerization management. Tuvatexib is being explored for targeted cytotoxic activity in precancerous skin lesions. Other pipeline agents, including RLS-1496 are under investigation for their potential to provide more selective action, reduced treatment duration, and improved safety profiles compared with existing topical therapies.

Explore comprehensive drug insights and treatment updates in our in-depth Actinic Keratosis Market Forecast @ Actinic Keratosis Clinical Trials Assessment

Scope of the Actinic Keratosis Market Report

• Study Period: 2022-2036
• Coverage: 7MM
• Actinic Keratosis Companies- Athenex, Almirall, Vidac Pharma, Promius Pharma and others.
• Actinic Keratosis Therapies- AVX001, VDA-1102, Fluorouracil, Imiquimod 3.75% Cream, Tirbanibulin 2.5 mg ointment, KX01 ointment 1%, Tretinoin 0,05% cream, Bimiralisib, Solcera, LAS41005, LAS106521 and others.
• Actinic Keratosis Therapeutic Assessment: Actinic Keratosis current marketed and Actinic Keratosis emerging therapies
• Actinic Keratosis Market Dynamics: Actinic Keratosis market drivers and Actinic Keratosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Actinic Keratosis Unmet Needs, KOLs’ views, Analysts’ views, Actinic Keratosis Market Access and Reimbursement

Table of Contents

1. Actinic Keratosis Market Report Introduction

2. Executive Summary for Actinic Keratosis

3. SWOT analysis of Actinic Keratosis

4. Actinic Keratosis Patient Share Overview at a Glance

5. Actinic Keratosis Market Overview at a Glance

6. Actinic Keratosis Disease Background and Overview

7. Actinic Keratosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Actinic Keratosis

9. Actinic Keratosis Current Treatment and Medical Practices

10. Actinic Keratosis Unmet Needs

11. Actinic Keratosis Emerging Therapies

12. Actinic Keratosis Market Outlook

13. Country-Wise Actinic Keratosis Market Analysis

14. Actinic Keratosis Market Access and Reimbursement of Therapies

15. Actinic Keratosis Market Drivers

16. Actinic Keratosis Market Barriers

17. Actinic Keratosis Appendix

18. Actinic Keratosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/actinic-keratosis-market